Pharmacogenomic considerations in the opioid management of pain by Jannetto, Paul J & Bratanow, Nancy C
Current management of pain
The control of pain, a complex and subjective experience, 
is  critical  to  clinical  success  in  caring  for  patients. 
Opioids  such  as  oxycodone,  methadone  and  morphine 
are  the  recommended  therapy  by  the  World  Health 
Organization and the European Association for Palliative 
Care for moderate to severe pain [1,2]. However, the use 
of  opioids  in  pain  management  requires  careful  dose 
escalation  and  empirical  adjustments  based  on  clinical 
response and the presence of side effects or adverse drug 
reactions (ADRs). Unfortunately, successful pain manage­
ment treatment ­ defined as adequate analgesia without 
excessive  adverse  effects  [3]  ­  can  be  challenging  [4]. 
Unpleasant opioid side effects, such as nausea, vomiting, 
constipation and sedation, are common and can lead to 
absence from work, poor performance at work and the 
resulting risk of job loss, and a diminished quality of life. 
The  most  serious  issues  involve  the  risk  of  sedation, 
depression of respiration and unintentional death due to 
inability  or  poor  ability  to  metabolize  the  medications 
successfully.  An  individual’s  genetic  makeup  may  pre­
dispose the patient to these adverse effects and reduced 
efficacy. Pharmacogenomic approaches offer insight into 
the  genetic  variables  that  can  affect  a  drug’s  uptake, 
transport, activation of its target, metabolism, interaction 
with  other  medications  and  excretion.  The  use  of 
pharma  co  genomics  in  patients  requiring  pain  manage­
ment  can  lead  to  more  efficient  opioid  selection,  dose 
optimization  and  minimization  of  ADRs  to  improve 
patient outcome.
Clinically relevant candidate genes for pain 
management
Cellular transporters control the uptake, distribution and 
elimination of drugs. P­glycoprotein is an efflux trans­
porter  also  called  adenosine  triphosphate­binding 
cassette, subfamily B, member 1 (ABCB1) or multidrug 
resistance  1  (MDRD1)  [5].  It  is  expressed  in  hepatic, 
intestinal  and  renal  epithelial  cells  and  also  on  the 
luminal  side  of  endothelial  cells  in  the  blood­brain 
barrier, and it is a major determinant of the pharmaco­
kinetics and pharmacodynamics of several opioids (such 
as morphine, methadone and fentanyl) commonly used 
to treat pain [5]. Genetic variants (such as 3435C>T) in 
P­glycoprotein  have  been  associated  with  variability  of 
pain relief in cancer patients treated with morphine [6]. 
The  analgesic  effects  of  morphine  are  mediated  by  its 
interaction at the µ­opioid receptor located in the central 
nervous  system  (CNS).  P­glycoprotein  can  limit  the 
concentration  of  pain  management  drugs,  such  as 
morphine, in the brain because it actively pumps drugs 
out of the CNS. As a result, homozygous carriers of the 
3435C>T variant (TT carriers) experience greater pain 
relief than heterozygous (CT) or homozygous wild­type 
(CC) carriers, presumably because higher concentrations 
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© 2010 BioMed Central Ltdof morphine can be achieved in the CNS [6]. Table 1 lists 
the clinically relevant pharmacogenomic targets for pain 
management.
The cytochrome P450 (CYP) system is responsible for 
metabolizing a wide range of therapeutic agents used for 
pain  relief.  CYP2D6  is  especially  important  for  the 
activation or inactivation of several opioids used to treat 
pain,  including  codeine,  oxycodone  and  tramadol  [7]. 
Typically, the genetic variability of CYP can be grouped 
into  four  phenotypes:  ultrarapid  metabolizers  (UM), 
extensive metabolizers (EM), intermediate metabolizers 
(IM) and poor metabolizers (PM). UM­classified patients 
typically contain multiple copies of a gene, which results 
in  an  increase  in  drug  metabolism  [8].  EM­classified 
patients are characteristic of the normal population and 
have a single wild­type copy of the gene, whereas IM­
classified patients show decreased enzymatic activity and 
PM­classified  patients  have  no  detectable  enzymatic 
activity [8]. Codeine is a prodrug that requires demethy­
lation  to  its  active  metabolite  morphine  by  CYP2D6 
before  it  can  exert  an  analgesic  effect.  As  a  result, 
CYP2D6  PM­classified  patients  experience  ineffective 
analgesia and increased side effects from the parent drug 
(codeine) [7]. On the other hand, CYP2D6 UM­classified 
patients  prescribed  codeine  for  pain  management 
generate  extensive  concentrations  of  morphine,  which 
can lead to ADRs [9].
Tramadol,  another  opioid  commonly  used  for  pain 
management,  produces  analgesia  by  the  synergistic 
action of its two enantiomers and their metabolites [7]. 
Tramadol undergoes metabolism by CYP2D6 to an active 
metabolite  (O­desmethyl  tramadol),  which  has  greater 
affinity  for  the  µ­opioid  receptor  than  does  the  parent 
compound [7]. Genetic variations in CYP2D6 have been 
shown to account for some of the variable pain response 
in the post­operative period because the CYP2D6 activity 
has a clinically relevant impact on the level of analgesia 
mediated by the µ­opioid receptor [10].
Another  important  genetic  target  is  uridine 
diphosphate­glucuronosyltransferase  2B7  (UGT2B7), 
which metabolizes morphine to morphine 3­glucuronide 
(M3G)  and  morphine  6­glucuronide  (M6G).  The  latter 
has a higher analgesic potency than the parent compound 
[11]. Morphine is commonly used to control moderate 
and  severe  pain  associated  with  sickle  cell  disease. 
Darbari  et  al.  [12]  showed  that  the  presence  of  the 
UGT2B7  ­840G>A  genotypes  (GG  and  GA)  were 
associated with lower M3G:morphine and M6G:morphine 
ratios  than  AA  genotypes.  As  a  result,  genetic  poly­
morphisms in UGT2B7 have been shown to decrease the 
hepatic  clearance  of  morphine,  which  translates  into 
lower dosage requirements of morphine [12]. In another 
study [13], the UGT2B7*2 polymorphism (802C>T) was 
also  shown  to  be  associated  with  the  frequency  of 
morphine­induced  ADRs  (nausea)  in  cancer  patients. 
The  authors  showed  that  the  frequency  of  nausea  was 
higher in patients without the UGT2B7*2 allele [13].
Furthermore,  the  efficacy  of  opioid  analgesia  can  be 
enhanced  by  the  co­administration  of  catecholamines, 
which  are  involved  in  the  modulation  of  pain  [14]. 
Catechol­O­methyltransferase  (COMT)  is  responsible 
for  the  inactivation  of  catecholamines  (dopamine, 
adrena  line  and  norepinephrine).  As  a  result,  genetic 
variability in the COMT gene can contribute to differ­
ences in pain sensitivity and response to analgesics. It has 
been  shown  that  a  common  variant  allele  (1947G>A; 
Rs4680)  results  in  a  three­  to  fourfold  reduction  in 
COMT  enzyme  activity  [15].  Homozygous  wild­type 
(GG) cancer patients required higher doses of morphine 
to control pain than heterozygous or homozygous variant 
(AA) alleles [16,17].
Finally, the µ­opioid receptor encoded by the opioid­
receptor­like  1  (OPRM1)  gene  is  the  primary  site  of 
action  for  most  of  the  commonly  used  opioids.  The 
118A>G  polymorphism  in  this  gene  results  in  less 
effective  opioid  analgesia,  as  reported  with  cancer 
patients  with  homozygous  variant  alleles  (GG)  who 
required  higher  morphine  doses  for  pain  relief  than 
homozygous wild­type (AA) participants [18]. In another 
study  [19],  Chou  et  al.  investigated  the  correlation 
between  the  118A>G  polymorphism  and  patient­
controlled morphine consumption in patients undergoing 
Table 1. Clinically relevant pharmacogenomic targets for pain management
Gene  Variant  Analgesics affected  Consequence of genetic variation
ABCB1  3435C>T  Morphine  Homozygous variants cause increased efficacy 
CYP2D6  1846G>A, 2549A>del  Codeine, oxycodone, tramadol  Poor metabolizers (PM; variants) have more adverse drug reactions and less 
      efficacy
UGT2B7  -840G>A, 802C>T; *2  Morphine  Homozygous variants require lower doses of morphine for efficacy; 
      UGT2B7*2 variants have less side effects (nausea) with morphine
COMT  1947G>A, (Rs4680)  Morphine  Homozygous variants have a three- to fourfold decrease in COMT activity; 
      wild-type patients require higher doses of morphine for efficacy than variant  
      patients
OPRM1  118A>G  Morphine, M6G  Homozygous variants cause decreased effectiveness and increased dose 
      requirements
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variants  (GG)  consumed  approximately  60%  more 
morphine  than  patients  who  were  heterozygous  or 
homozygous  wild­type  (AA)  during  the  first  48­hour 
post­operative  period.  Patient  demographics,  reported 
pain  and  other  factors  did  not  differ  between  the 
genotype groups. In a similar study [20], women who had 
homozygous  variants  for  the  118A>G  polymorphism 
required 30% more morphine to achieve adequate pain 
control than those who were wild type (AA) during the 
first  24  hours  after  a  total  abdominal  hysterectomy. 
Finally, a significant relationship between the degree of 
pain  relief  and  the  118A>G  genotypes  was  shown  in 
cancer  patients  being  treated  with  morphine  over  the 
first  2  months  of  therapy  [6].  In  the  first  7  days  of 
morphine treatment, patients homozygous for the wild­
type allele (AA) had more pronounced decrease in pain 
from baseline than those who were homozygous variants 
(GG), whose response was almost undetectable [6].
Limitations and future directions of 
pharmacogenomics for pain management
Genomic variations clearly influence pain sensitivity, the 
likelihood of developing chronic pain and the response to 
pharmacotherapy  for  the  management  of  pain  [21,22]. 
Pharmacogenomic polymorphisms are definitely impor­
tant  in  the  interindividual  variability  in  the  analgesic 
effects  and  occurrence  of  ADRs  of  commonly  used 
medications  prescribed  for  pain  management,  but 
genetic factors will provide only a partial answer to the 
interindividual  variability  observed.  Other  factors, 
includ  ing  biological  variations  (ethnicity,  age  and 
gender),  environmental  factors  (smoking  status),  co­
morbidity  and  co­medications  (potential  for  drug­drug 
interactions) must be considered along with the genetic 
variations because together they all affect the pharmaco­
kinetics and pharmacodynamics of medications used for 
pain management. Additional studies are also needed to 
characterize the combined effects of multiple genes along 
with demographic and clinical variables in selecting the 
appropriate opioid and predicting the appropriate opioid 
dose in patients with pain. Large, randomized prospective 
studies  are  needed  to  develop  appropriate  dosing  or 
treatment algorithms to facilitate the use of genotyping 
information  appropriately  by  physicians.  Furthermore, 
the continued development of regulator­approved geno­
typing assays to identify these variant alleles will allow 
greater  access  to  this  information  to  aid  in  day­to­day 
clinical  decisions  for  acute  and  chronic  pain  manage­
ment. The benefits of patient care and safety will result in 
the incorporation of this knowledge into the standard of 
care for anesthesiologists and pain management physi­
cians. In the near future, pharmacogenomic approaches 
in pain management could lead to individualized therapy 
to best select the appropriate analgesic from the onset to 
provide  sustained  efficacy  with  the  lowest  side  effect 
profile.
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